[go: up one dir, main page]

WO2006040318A3 - Inhibiteurs de kinase gamma p13 pour le traitement de l'anemie - Google Patents

Inhibiteurs de kinase gamma p13 pour le traitement de l'anemie Download PDF

Info

Publication number
WO2006040318A3
WO2006040318A3 PCT/EP2005/055156 EP2005055156W WO2006040318A3 WO 2006040318 A3 WO2006040318 A3 WO 2006040318A3 EP 2005055156 W EP2005055156 W EP 2005055156W WO 2006040318 A3 WO2006040318 A3 WO 2006040318A3
Authority
WO
WIPO (PCT)
Prior art keywords
anaemia
treatment
gamma inhibitors
kinase gamma
selective
Prior art date
Application number
PCT/EP2005/055156
Other languages
English (en)
Other versions
WO2006040318A2 (fr
Inventor
Reinhard Wetzker
Angelika Mueller
Christian Rommel
Original Assignee
Applied Research Systems
Reinhard Wetzker
Angelika Mueller
Christian Rommel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0517416-3A priority Critical patent/BRPI0517416A/pt
Priority to MX2007004302A priority patent/MX2007004302A/es
Priority to CA002580480A priority patent/CA2580480A1/fr
Priority to EP05801722A priority patent/EP1807075A2/fr
Priority to US11/664,969 priority patent/US20090042773A1/en
Priority to EA200700848A priority patent/EA200700848A1/ru
Application filed by Applied Research Systems, Reinhard Wetzker, Angelika Mueller, Christian Rommel filed Critical Applied Research Systems
Priority to AU2005293556A priority patent/AU2005293556A1/en
Priority to JP2007536166A priority patent/JP2008515955A/ja
Publication of WO2006040318A2 publication Critical patent/WO2006040318A2/fr
Publication of WO2006040318A3 publication Critical patent/WO2006040318A3/fr
Priority to IL182110A priority patent/IL182110A0/en
Priority to NO20072393A priority patent/NO20072393L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'inhibiteurs sélectifs de kinase gamma PD pour fabriquer un médicament destiné à traiter des troubles associés à une déficience érythrocytaire. En particulier, l'invention concerne l'utilisation d'inhibiteurs sélectifs de la kinase gamma P13, par exemple des dérivés à benzène fusionné azolidinone-vinyle substitué pour le traitement d'une anémie, notamment une anémie hémolytique, une anémie aplastique et une anémie érythrocytaire pure. Les inhibiteurs de l'invention sont de formule (I). Dans cette formule, A, X, Y1, Y2, Z, n, R1 et R2 sont décrits en détail dans la description.
PCT/EP2005/055156 2004-10-12 2005-10-11 Inhibiteurs de kinase gamma p13 pour le traitement de l'anemie WO2006040318A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2007004302A MX2007004302A (es) 2004-10-12 2005-10-11 Inhibidores de pi3 cinasa gamma para el tratamiento de anemia.
CA002580480A CA2580480A1 (fr) 2004-10-12 2005-10-11 Inhibiteurs de kinase gamma p13 pour le traitement de l'anemie
EP05801722A EP1807075A2 (fr) 2004-10-12 2005-10-11 Inhibiteurs de la kinase pi3 gamma pour le traitement de l'anémie
US11/664,969 US20090042773A1 (en) 2004-10-12 2005-10-11 P13 kinase gamma inhibitors for the treatment of anaemia
EA200700848A EA200700848A1 (ru) 2004-10-12 2005-10-11 Ингибиторы pi3-гамма-киназы для лечения анемии
BRPI0517416-3A BRPI0517416A (pt) 2004-10-12 2005-10-11 inibidores de pi3 quinase gama para o tratamento de anemia
AU2005293556A AU2005293556A1 (en) 2004-10-12 2005-10-11 PI3 Kinase gamma inhibitors for the treatment of anaemia
JP2007536166A JP2008515955A (ja) 2004-10-12 2005-10-11 貧血の治療のためのＰＩ３キナーゼγ阻害剤
IL182110A IL182110A0 (en) 2004-10-12 2007-03-22 P13 kinase gamma inhibitors for the treatment of anemia
NO20072393A NO20072393L (no) 2004-10-12 2007-05-09 P13-kinase gamma hemmere for behandling av anemi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104997.4 2004-10-12
EP04104997 2004-10-12

Publications (2)

Publication Number Publication Date
WO2006040318A2 WO2006040318A2 (fr) 2006-04-20
WO2006040318A3 true WO2006040318A3 (fr) 2006-08-10

Family

ID=34929693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/055156 WO2006040318A2 (fr) 2004-10-12 2005-10-11 Inhibiteurs de kinase gamma p13 pour le traitement de l'anemie

Country Status (14)

Country Link
US (1) US20090042773A1 (fr)
EP (1) EP1807075A2 (fr)
JP (1) JP2008515955A (fr)
KR (1) KR20070073857A (fr)
CN (1) CN101056633A (fr)
AU (1) AU2005293556A1 (fr)
BR (1) BRPI0517416A (fr)
CA (1) CA2580480A1 (fr)
EA (1) EA200700848A1 (fr)
IL (1) IL182110A0 (fr)
MX (1) MX2007004302A (fr)
NO (1) NO20072393L (fr)
WO (1) WO2006040318A2 (fr)
ZA (1) ZA200702435B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604030B2 (en) 2009-03-27 2013-12-10 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical containing same

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5209311B2 (ja) * 2004-09-03 2013-06-12 メルク セローノ ソシエテ アノニム ピリジンメチレンアゾリジノン及びホスホイノシチド阻害剤としてのその使用
EP2046333A4 (fr) * 2006-07-24 2010-09-15 Glaxosmithkline Llc Dérivés de thiozolidinedione utilisés en tant qu'inhibiteurs de la p13-kinase
WO2009017822A2 (fr) 2007-08-02 2009-02-05 Amgen Inc. Modulateur de la pi3 kinase et leurs procédés d'utilisation
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2010027002A1 (fr) * 2008-09-05 2010-03-11 塩野義製薬株式会社 Derive de morpholine à cycles condensés ayant une activite inhibitrice de pi3k
EP2440556A1 (fr) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de la phosphatidylinositol 3-kinase
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
WO2012027495A1 (fr) 2010-08-27 2012-03-01 University Of The Pacific Analogues de pipérazinylpyrimidine en tant qu'inhibiteurs de protéine kinase
CN102584809B (zh) * 2011-01-14 2014-12-24 湘北威尔曼制药股份有限公司 胺基噻唑烷酮化合物及其制备方法与在制备抗肿瘤药物中的应用
US8901145B2 (en) 2011-04-22 2014-12-02 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
JP6215832B2 (ja) 2011-11-04 2017-10-18 ジャスコ ファーマスーティカルズ エルエルシーＪａｓｃｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， ＬＬＣ アミノピリミジンキナーゼ阻害剤
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
AU2014391608A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013981A (es) 2014-04-24 2016-11-15 Novartis Ag Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa.
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
AR114793A1 (es) 2018-04-18 2020-10-14 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JPWO2022163843A1 (fr) * 2021-02-01 2022-08-04

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047760A2 (fr) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Nouveaux composes chimiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EA011807B1 (ru) * 2002-07-10 2009-06-30 Лаборатуар Сероно Са Азолидинонвинильные производные конденсированного бензола

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047760A2 (fr) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Nouveaux composes chimiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604030B2 (en) 2009-03-27 2013-12-10 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical containing same

Also Published As

Publication number Publication date
KR20070073857A (ko) 2007-07-10
EA200700848A1 (ru) 2007-10-26
CA2580480A1 (fr) 2006-04-20
NO20072393L (no) 2007-05-09
WO2006040318A2 (fr) 2006-04-20
MX2007004302A (es) 2007-06-07
BRPI0517416A (pt) 2008-10-07
CN101056633A (zh) 2007-10-17
US20090042773A1 (en) 2009-02-12
ZA200702435B (en) 2008-06-25
AU2005293556A1 (en) 2006-04-20
IL182110A0 (en) 2007-07-24
EP1807075A2 (fr) 2007-07-18
JP2008515955A (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2006040318A3 (fr) Inhibiteurs de kinase gamma p13 pour le traitement de l'anemie
WO2007048064A3 (fr) Aminopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
WO2006021884A3 (fr) Composes d'aminoheteroaryle enantiomeriquement purs utilises comme inhibiteurs de proteine kinase
TW200833324A (en) Sulfonamide derivatives
WO2007023110A3 (fr) Inhibiteurs de la map-kinase p38 et ses methodes d'utilisation
NO20071593L (no) Pyrimidinderivater
WO2008017932A3 (fr) HÉTÉROCYCLES UTILES EN TANT QU'inhibiteurs d'anhydrase carbonique
WO2005118557A3 (fr) Composes organiques
WO2006084017A3 (fr) Composes pyrimidine a substitution phenyle utilises en tant qu'inhibiteurs de kinases
UA94065C2 (en) Dihydropseudoerythromycin derivatives
WO2006005609A3 (fr) Derives d'oxindole substitues, et medicaments les renfermant
WO2005075425A3 (fr) Derives de bisaryluree
WO2006116733A3 (fr) Inhibiteurs des proteines kinases
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
WO2005118541A3 (fr) Composes organiques
WO2007099171A3 (fr) Bicyclopyrazoles actifs comme inhibiteurs de la kinase
WO2007068728A3 (fr) Pyrrolopyridinones n-substituees actives en tant qu'inhibiteurs de kinase
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
WO2006005726A3 (fr) Composes organiques
WO2006000371A3 (fr) Derives de pyrimidine
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2008104473A3 (fr) Inhibiteurs de kinase et procédés d'utilisation de ces derniers
WO2008015139A3 (fr) Inhibiteurs de zinc protéases substituées par thioaryle et leur utilisation
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2580480

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005293556

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 182110

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007/02435

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2450/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005801722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004302

Country of ref document: MX

Ref document number: 2007536166

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005293556

Country of ref document: AU

Date of ref document: 20051011

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005293556

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077010007

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580038804.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200700848

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11664969

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005801722

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0517416

Country of ref document: BR